Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

Basit Öğe Kaydı
dc.contributor.authorCicin, Irfan
dc.contributor.authorGumus, Mahmut
dc.contributor.authorUncu, Dogan
dc.contributor.authorOzkan, Metin
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorElkiran, Tamer E.
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorKaraoglu, Aziz
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Feyyaz
dc.contributor.authorTurna, Hande
dc.contributor.authorKara, Oguz
dc.contributor.authorOzyilkan, Ozgur
dc.contributor.authorGuducu, Merve
dc.contributor.authorErdogan, Alper
dc.contributor.authorUslu, Ruchan
dc.date.accessioned2019-10-27T11:08:02Z
dc.date.available2019-10-27T11:08:02Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET -- JUN 02-07, 2017 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/JCO.2017.35.15_suppl.e15055
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.urihttps://doi.org/10.1200/JCO.2017.35.15_suppl.e15055
dc.identifier.urihttps://hdl.handle.net/11454/32115
dc.identifier.volume35en_US
dc.identifier.wosWOS:000411895707157en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleCharacteristics of Turkish colorectal cancer patients and bevacizumab preference.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu